Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) in the management of primary mediastinal B-cell lymphoma: a subgroup analysis of the UK NCRI R-CHOP 14 versus 21 trial.
- Gleeson, M
- Hawkes, EA
- Cunningham, D
- Chadwick, N
- Counsell, N
- Lawrie, A
- Jack, A
- Smith, P
- Mouncey, P
- Pocock, C
- Ardeshna, KM
- Radford, J
- McMillan, A
- Davies, J
- Turner, D
- Kruger, A
- Johnson, PWM
- Gambell, J
- Linch, D
Publication date
November 2016
DOI Publisher
Wiley Journal
British Journal of HaematologyAbstract
We performed a subgroup analysis of the phase III UK National Cancer Research Institute R-CHOP-14 versus R-CHOP-21 (two- versus three-weekly rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone) trial to evaluate the outcomes for 50 patients with World Health Organization 2008 classified primary mediastinal B-cell lymphoma identified from the trial database. At a median follow-up of 7·2 years the 5-year progression-free survival and overall survival was 79·8% and 83·8%, respectively. An exploratory analysis raised the possibility of a better outcome in those who received R-CHOP-14 and time intensification may still, in the rituximab era, merit testing in a randomised trial in this subgroup of patients
Add to ORKG